Immediate Impact

1 from Science/Nature 59 standout
Sub-graph 1 of 21

Citing Papers

Cefepime–Taniborbactam in Complicated Urinary Tract Infection
2024 Standout
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
2024 Standout
5 intermediate papers

Works of Angela Wardman being referenced

Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
2018
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
2016

Author Peers

Author Last Decade Papers Cites
Angela Wardman 292 390 176 6 444
Vassiliki Papaioannou 191 361 167 5 403
Katrina Yates 330 390 227 8 471
David van Veenhuyzen 205 250 126 7 376
Mitsuaki Machida 209 271 109 6 405
Christopher Cortes 282 403 120 7 431
Michelle Earley 291 419 165 16 510
Martha Nepka 275 438 171 5 506
Valentina Galfo 192 321 107 17 402
Daniel Cloutier 183 235 170 15 497
Tsukasa Ito-Horiyama 359 445 114 6 508

All Works

Loading papers...

Rankless by CCL
2026